Clinical trials: Relapsed Hematologic Malignancy, open to volunteers
Relapsed Acute Myeloid Leukemia
Imetelstat Combinations in Relapsed AML
IMAGINE is a two-part trial to evaluate the safety and preliminary efficacy of imetelstat in combination with azacitidine with or without venetoclax in patients with relapsed or refractory AML.
- Trial name
- IMAGINE (NCT07320235)
- Testing
- Imetelstat, Azacitidine, Venetoclax
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Douglas Tremblay
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL)
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies
- Conditions
- Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma)
- Trial name
- COURAGE (NCT06914037)
- Testing
- CHT101
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd)…
- Trial name
- Iber-KDd (NCT05896228)
- Testing
- Iberdomide, Carfilzomib, Daratumumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Benjamin T Diamond, MD
Multiple Myeloma, Relapse Multiple Myeloma
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
This is an open label, abbreviated (3+3) dose escalation study in subjects with RRMM, followed by an extension phase at the selected safe dose.
- Trial name
- NCT05243212
- Testing
- CAR-BCMA
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Sheba Medical Center
Hematologic Malignancy, AML
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN
- Trial name
- NCT05476770
- Testing
- Tagraxofusp, Fludarabine, Cytarabine
- Where
- 31 sites in United States, Australia
- Volunteers
- 54 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Multiple Myeloma in Relapse
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
Multiple myeloma is the second most common haematological cancer. Recent innovations have made it possible for relapsed/refractory patients to benefit from the innovative immunotherapy of bispecific antibodies.
- Trial name
- AmbuSpé (NCT06846905)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Toulouse
Acute Myeloid Leukemia
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia…
- Trial name
- RIVER-81 (NCT06191263)
- Testing
- RVU120, Venetoclax
- Where
- 37 sites in France, Italy and 2 more
- Volunteers
- 98 people
- Sponsor
- Ryvu Therapeutics SA
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
This phase 2 study aims to confirm the efficacy observed in the prior phase 1 trial in Cohort 1 and to evaluate the safety of IFN-γ in combination with DLI in Cohort 2, the haploidentical donor alloSCT recipient cohort.
- Trial name
- NCT06529731
- Testing
- Interferon gamma-1b, Donor Leukocyte Infusion (DLI)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sawa Ito, MD
Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
This is a non-interventional observational study aiming to evaluate the quality of life, efficacy, and safety of advanced immuno-oncology agents versus conventional immuno-oncology therapies in patients with relapsed or…
- Trial name
- NCT07051850
- Testing
- Bispecific antibody, Antibody-Drug Conjugate, Monoclonal antibody
- Where
- South Korea
- Volunteers
- 174 people
- Sponsor
- Sung-Soo Park
AML (Acute Myelogenous Leukemia)
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
This is a single-center, prospective, single-arm, exploratory clinical study. To explore the efficacy and safety of avapritinib in patients with recurrent acute myeloid leukemia after allogeneic hematopoietic stem cell…
- Trial name
- NCT06783790
- Testing
- Avapritinib, azacitidine, Venetoclax
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma (MM)
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
This is a prospective, single-arm, exploratory Phase II clinical study evaluating the efficacy and safety of HP-001 capsules in combination with dexamethasone in patients with relapsed or refractory multiple myeloma (RRMM) with…
- Trial name
- BEYOND-MM 001 (NCT07811986)
- Testing
- HP-001, Dexamethasone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells.
- Conditions
- B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma
- Trial name
- NCT07168486
- Testing
- CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Maryland, Baltimore
Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma
- Trial name
- NCT03136146
- Testing
- Bortezomib, Clofarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
AML, AML With Mutated NPM1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA…
- Conditions
- AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar
- Trial name
- NCT06001788
- Testing
- Ziftomenib, Fludarabine, Idarubicin
- Where
- 45 sites in United States, Italy and 1 more
- Volunteers
- 171 people
- Sponsor
- Kura Oncology, Inc.
Lymphoma, Lymphoid Hematological Malignancies
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy.
- Trial name
- NCT07472972
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Multiple Myeloma
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.
- Trial name
- NCT03110822
- Testing
- Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
- Where
- 13 sites in United States
- Volunteers
- 134 people
- Sponsor
- Oncotherapeutics
B Lymphocytic Leukemia, B Lymphoblastic Lymphoma
CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children
- Trial name
- NCT06355739
- Testing
- CAR T cell injection
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Zhu Xiaofan
Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML
The purpose of this prospective, multi-center, single-arm, phase 2 study is to evaluate the efficacy and safety of a combination regimen of mitoxantrone hydrochloride liposome injection, standard-dose of cytarabine and venetoclax…
- Trial name
- NCT06621212
- Testing
- mitoxantrone hydrochloride liposome, Cytarabine, Venetoclax
- Where
- China
- Volunteers
- 72 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Relapsed Refractory Multiple Myeloma (RRMM)
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching a drug called REGN17372 used with another drug called linvoseltamab (each individually called "study drug" or "study drugs" when combined) in participants with relapsed (when a tumor comes back) or…
- Trial name
- NCT07455851
- Testing
- Linvoseltamab, REGN17372+Linvoseltamab
- Where
- 9 sites in Australia, Greece
- Volunteers
- 150 people
- Sponsor
- Regeneron Pharmaceuticals
Hematological Malignancy
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
To determine the safety, efficacy and optimal cell dose of CAR 5/IL15-transduced CB-NK cells in patients with relapsed/refractory T-cell malignances, mantle cell lymphoma, and chronic lymphocytic leukemia.
- Trial name
- NCT05110742
- Testing
- Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center